Mission
The Osteosarcoma Institute (OSI) is dedicated to addressing the urgent need for new treatment options for osteosarcoma, a rare and aggressive form of bone cancer. Founded in 2015, OSI collaborates with leading researchers, clinicians, and industry to fund innovative clinical trials and research aimed at improving patient outcomes and finding a cure for this devastating disease.
Basic Information
Tax-Exempt
Founded in
2017
EIN
82-2921815
Total Assets
$6.111 million
UN Sustainable Development Goals Supported
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
Showing 3 of 3 goals
At a Glance
Breakthrough Research Grants
OSI awarded $1.1 million to three innovative research projects aimed at osteosarcoma.
Patient Support through OSI Connect
A dedicated resource offering assistance to osteosarcoma patients and their families.
Building Awareness and Community
Advocacy initiatives aimed at raising awareness of osteosarcoma across the United States.
Impact Stats
$6.8M
Total Funding Committed
Funding for Innovative Research
The OSI has committed $6.8 million to osteosarcoma clinical trials and research studies since its inception.
varies annually
Number of Patients Served
Development of OSI Connect
Introduction of OSI Connect, a resource for patients to obtain expert advice and assistance with osteosarcoma.
Our Programs
OSI Connect
A free, easy-to-use resource for patients diagnosed with osteosarcoma, or those who have experienced a relapse.
Learn MoreMIP Score (Beta)
The MIP Score is in beta! We'd love any feedback you may have.
The MIP Score and it's methodology is purely used as a way to visualize how a nonprofits public financial data compares against others. It doesn't reflect the unique circumstances and impact that a nonprofit has.The MIP Score should never be used to say one charity is better than another.
Overall Score
54
50
/100
Program Expense Ratio
71.38%
8
/20
Program Revenue Growth
0.00%
2
/20
Leverage Ratio
0.002294
20
/20
Working Capital Ratio
4.408
18
/20
Fundraising Efficiency
0
2
/20
Latest Filing Data: Form 990
Fiscal Year:2022
Source:Source: Self-reported by organization
Financial Details
Revenue
| Category | Amount | Percentage |
|---|---|---|
| Contributions, Gifts, and Grants | 742.9K | 99.05% |
| Program Services | 0 | 0.00% |
| Investment Income | 7.1K | 0.95% |
| Sales of Non-Inventory Assets | 0 | 0.00% |
| Other Notable Sources | 0 | 0.00% |
| Total Revenue | 750K | 100.00% |
Related Nonprofits
Mycoses Study Group Education and Research Consortium
Med Research
Medical Research InstituteTaho Institute for Rural Health Research
Med Research
Medical Research InstituteSeattle Science Foundation
Med Research
Medical Research InstituteDigital Medicine Society Inc.
Med Research
Medical Research InstituteCci Research Foundation
Med Research
Medical Research Institute